Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CPA3 | P15088 | 3/20 | 0.60 |
| ▸ | PTGES | O14684 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 10/20 | 0.55 |
| ▸ | MMP1 | P03956 | 5/20 | 0.55 |
| ▸ | MMP3 | P08254 | 5/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9209348 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9653480 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9655121 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL5179711 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10957172 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10960336 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10955140 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL3242850 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9653477 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10550611 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925846-B2 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10925846-B2 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-02-23 | — | — | US | disclosed |
| CN-106999459-B | Phenyl ketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | 里米诺生物科学有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20190038580-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARAMCEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Liminal Biosciences Limited (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20190038580-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARAMCEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Liminal Biosciences Limited (GB) | 2019-02-07 | — | — | US | disclosed |
| CN-106999459-A | Phenyl ketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | 普罗米蒂克医药SMT有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016054725-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| CN-102510865-B | Nitrogen-containing spiro compound and pharmaceutical use thereof | JAPAN TOBACCO INC | 2015-04-15 | — | — | CN | disclosed |
| CN-102510865-A | Nitrogen-containing spiro compound and pharmaceutical use thereof | JAPAN TOBACCO INC | 2012-06-20 | — | — | CN | disclosed |
| EP-0546338-B1 | Mesomorphic compound, liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KK (JP) | 1998-02-04 | — | — | EP | disclosed |
| US-5385692-A | Improved response | CANON KABUSHIKI KAISHA (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0546338-A1 | Mesomorphic compound, liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-4780542-A | REACTING AN ACID WITH AN ALKYL CHLOROFORMATE TO GIVE AN ANHYDRIDE, THEN WITH AMINE OR ALCOHOL | MONTEFIORE MEDICAL CENTER (US) | 1988-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925846-B2 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | NCEH1, CTSH, BCKDK | FOLH1 180/4885CYP1A2 2704/4885CPA3 185/4885 |
| US-20190038580-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARAMCEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PAH, NCEH1, CCNH | FOLH1 379/4885CYP1A2 2023/4885CPA3 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.